Introduction
Prostate cancer is the most common solid tumor in men in North America. The incidence is increasing and over 317 100 newly diagnosed cases and 41 400 cancerrelated deaths are reported (Wingo et al., 1995) . Although surgery or radiation therapy is eective for the treatment of localized tumors, there is no eective modality available for patients having advanced or metastatic tumors (Naitoh et al., 1998) . Hormonal therapy is only palliative, and chemotherapy is generally ineective. Therefore, in order to improve prognosis of prostate cancer, it is absolutely essential to explore a novel modality of treatment.
Telomerase is a ribonucleoprotein that adds telomeric repeats to the ends of chromosome (Blackburn, 1991) . Approximately 90% of malignant tumors of various origins express telomerase, whereas most of normal tissues do not (Kim et al., 1994; Bacchetti and Counter, 1995; Shay and Wright, 1996) . Without telomerase, normal cells lose some of telomeric DNA with each cell division, and enter senescence or stop proliferation when telomeres reach a critical length (Harley et al., 1990; Hastie et al., 1990; Allsopp et al., 1995) . In contrast, telomerase enables cancer cells to extend telomeres and continue to proliferate (de Lange, 1994; Bacchetti, 1996) . Recent demonstrations show that telomerase was detected in the vast majority of prostate cancer, but not in normal or benign prostatic hyperplasia tissues (Sommerfeld et al., 1996; Lin et al., 1997) . Thus, telomerase may represent a very strong candidate for targeted therapy of prostate cancer.
Recently, using an antisense oligonucleotide against human telomerase RNA component (hTR) linked to 2-5A (5'-phosphorylated 2'-5'-linked oligoadenylate), we have succeeded in inhibiting cell growth of malignant glioma cells in vitro and in vivo (Kondo et al., 1998a) . 2-5A is a mediator of one pathway of interferon actions. 2-5A activates RNase L that is ubiquitous in mammalian cells, resulting in single-stranded RNA cleavage after UN sequences (Clemens and Williams, 1978; Zhou et al., 1993) . Antisense against a certain target linked to 2-5A causes degradation of the targeted RNA in a highly speci®c manner, and enhances the potency of antisense (Torrence et al., 1993; Maran et al., 1994; Cirino et al., 1997) . The cytotoxic eect of 2-5A-anti-hTR is thought to be speci®c for telomerase-positive cells. It is therefore expected that telomerase-positive prostate cancer cells are also sensitive to 2-5A-anti-hTR treatment. In this study, we investigated the cytotoxic eect of 2-5A-antihTR on prostate cancer in vitro and in vivo. To further enhance the eect of 2-5A-anti-hTR, it was administrated in the presence of a cationic liposome. The ®ndings obtained in the present study indicate the involvement of caspase family in 2-5A-anti-hTRinduced apoptosis and its therapeutic potentiality for prostate cancer. activity was clearly demonstrated in both cell lines. In contrast, telomerase activity was not detected in the two ®broblast cell lines (MRC5 and WI38). The internal telomerase activity standard (ITAS) was expressed in all cell lines, which excluded the possibility of a false negative result due to Taq polymerase inhibitors.
Effects of 2-5A-anti-hTR on cell viability of prostate cancer Previously, we demonstrated that treatment with a test oligonucleotide, spA 4 -anti-hTR signi®cantly degraded hTR of malignant glioma cells after 5 h, while hTR was present in cell treated with control oligonucleotides (spA 2 -anti-hTR and spA 4 -anti-(M6)hTR) (Kondo et al., 1998a) . In this study, those three types of 2-5A-anti-hTR were used to test the eect on prostate cancer cell lines and ®broblast cells. Because the presence of a cationic liposome, Lipofectamine, enhanced the potency of antisense oligonucleotide, we mixed Lipofectamine with oligonucleotides in the present study. First, to determine the optimal ratio of 2-5A-anti-hTR to Lipofectamine, we mixed 2-5A-anti-hTR (0.5, 1.0, 2.0, or 5.0 mM) with Lipofectamine (0, 0.4, 0.8, or 1.2 ml) and treated PC3 cells every 24 h. The best eect on cell viability was observed when 0.5 mM 2-5A-anti-hTR mixed with 0.4 ml Lipofectamine was added every 24 h (data not shown). And the cytotoxic eect of 0.4 ml Lipofectamine was minimal. Therefore, the in vitro treatment with 2-5A-anti-hTR was performed in this ratio. As shown in Figure 2 , treatment with spA 4 ± antihTR signi®cantly reduced cell viability of prostate cancer cells in a time-dependent manner. The cell viability of PC3 cells after spA 4 -anti-hTR treatment for 2, 4, or 6 days was 88, 51 or 18%, respectively. In DU145 cells, the cell viability was reduced to 54, 34 or 9% 2, 4, or 6 days after treatment with spA 4 -anti-hTR, respectively. The cytotoxic eect of inactive spA 2 -antihTR or the mismatch spA 4 -anti-(M6)hTR was much less compared to spA 4 -anti-hTR, and the cell viability of PC3 and DU145 cells 6 days after treatment was 82 ± 101% and 56 ± 67%, respectively. Importantly, no signi®cant reduction in cell viability was observed for any of the oligonucleotides when used to treat the telomerase-negative ®broblast cells. The cell viability with spA 4 -anti-hTR treatment in MRC5 and WI38 cells was 83 and 96%, respectively. These results indicated that 2-5A-anti-hTR was speci®cally eective for telomerase-positive cells, PC3 and DU145, but not telomerase-negative cells such as ®broblasts. Apoptotic cell death with 2-5A-anti-hTR treatment
The in vitro experiments demonstrated that cell viability was reduced in prostate cancer cell lines treated with 2-5A-anti-hTR and that the major eect was seen after only 2 days in DU145 cells and 4 days in PC3 cells after the treatment. These results suggested the possibility that treatment with 2-5A-anti-hTR not only inhibited cell growth, but also induced apoptotic cell death. Therefore, we used the TUNEL assay to examine the extent of apoptosis in the treated and untreated cells. To quantify the extent of apoptosis, the percentage of TUNEL-positive cells from a total of 300 cells was assessed in each treatment group. As shown in Figure 3 , the percentage of apoptotic cells after spA 4 -anti-hTR treatment was increased in a timedependent manner. The percentage of TUNEL-positive PC3 cells at days 1, 2 and 3 was 11, 14 and 74%, respectively. There was a large increase in TUNELpositive cells between days 2 and 3. In contrast, only 4 ± 10% cells were TUNEL positive 3 days after the treatment with control oligonucleotides (spA 2 -anti-hTR and spA 4 -anti-(M6)hTR), respectively. These results indicated that the cytotoxic eect of 2-5A-anti-hTR was mainly due to induction of apoptosis.
Effect of 2-5A-anti-hTR treatment on the mRNA expressions of apoptosis-associated genes
The TUNEL assays demonstrated that signi®cant apoptotic cell death was detected following treatment with spA 4 -anti-hTR, and that it was increased most signi®cantly between days 2 and 3. These observations raised the possibility that certain apoptotic pathways might be activated by the treatment. To detect which pathways were aected, mRNA expression levels of apoptosis-associated genes were investigated. Since the caspase and bcl families are widely known as apoptosis-associated molecules, we ®rst examined the mRNA levels of caspase family (caspase 1, 2S, 2L1, 3, 4, 6, 7, 8, 9 and 10A) and bcl family (bcl-2, bcl-X L , bcl-X S , Bak, Bax and MCL1) with ribonuclease protection assays. Overall, little change of mRNA was detected in either the caspases or bcl family during the 2-5A-antihTR treatment (data not shown). On the other hand, cyclin-dependent kinase inhibitors (CDKIs) have been shown to be associated with apoptosis in some cell types (Kondo et al., 1996; Wang and Walsh, 1996) . Recently, we demonstrated that the expressions of CDKIs such as p21 and p27 were enhanced by telomerase inhibition with antisense hTR vector (Kondo et al., 1998b) . Therefore, we also examined the expressions of CDKIs after treatment with 2-5A-anti-hTR. The mRNA expression level of p16 was increased to 3.4-fold on day 2 when compared to the untreated cells (P50.01, Figure 4 ). The expression of p27 was also increased to 2.5-fold on day 2 (P50.05). In contrast, treatment with spA 4 -anti-(M6)hTR in the presence of Lipofectamine or with Lipofectamine alone did not aect the expressions of p16 and p27. The expression of p21 was undetectable prior to and during the treatment. These results indicated that there was no change in mRNA expressions of the caspase and bcl families during the treatment with 2-5A-anti-hTR, whereas p16 and p27 were remarkably enhanced.
Activation of caspases
Although there was no change in mRNA levels of caspases, it was possible that caspases might be activated. It is because caspases are post-transcriptionally modi®ed. Therefore, we performed caspase inhibition assays to either con®rm or exclude the activation of caspases. 2-5A-anti-hTR treatment was performed every 24 h in the presence of a caspase inhibitor. Since DMSO is the solvent of caspase inhibitors, we added the same amount of DMSO to control cells without caspase inhibitors to compare cell viability. After 4 days treatment, PC3 cell viability with spA 4 -anti-hTR was reduced to 31% compared to the cells with Lipofectamine alone (Figure 5 ). Interestingly, adding ICE inhibitor (100 mM) increased the cell viability to 93% (P50.01 compared to spA 4 -anti-hTR alone). Additionally, incubation with CPP32b inhibitor (100 mM) resulted in recovering the cell viability to 74% (P50.03 compared to spA 4 -anti-hTR alone) ( Figure 5 ). As the cytotoxic eect of 0.4 ml Lipofectamine was minimal, it was speculated that the eect of Lipofectamine alone on caspases might be little, if any. Effects of 2-5A-anti-hTR on prostate cancer in vivo To investigate the eect of 2-5A-anti-hTR on prostate cancer cells in vivo, PC3 cells were subcutaneously inoculated into nude mice. When the tumors reached a mean volume of 50 mm 3 , they received daily injections of spA 4 -anti-hTR or spA 4 -anti-(M6)hTR in the presence of Lipofectamine, respectively. To determine the optimal ratio of 2-5A-anti-hTR to Lipofectamine, the oligonucleotides were mixed with 0, 0.3, or 1.0 ml of Lipofectamine. The treatment with 2-5A-anti-hTR (1 nmol) in the presence of 0.3 ml Lipofectamine showed a better antitumor eect than other modalities we treated (data not shown). After the treatment with spA 4 -anti-hTR (1 nmol) mixed with Lipofectamine (0.3 ml) for 7 days, the increase in PC3 tumor volume was just 14% whereas in controls treated with spA 4 -anti-(M6)hTR (1 nmol) with Lipofectamine (0.3 ml) it was 215% ( Figure 6A ) (P50.001). TUNEL staining of PC3 subcutaneous tumors inoculated into nude mice is shown in Figure 6B . Many apoptotic cells were detected in the tumor treated with spA 4 -anti-hTR ( Figure 6B-b) whereas few cells were stained in the control tumor treated with spA 4 -anti-(M6)hTR ( Figure  6B-a) . These results indicated that treatment with 2-5A-anti-hTR signi®cantly suppressed the in vivo growth of prostate cancer through induction of apoptosis.
Discussion
In this study, we have demonstrated the cytotoxic eect of 2-5A-anti-hTR on prostate cancer cells in vitro and in vivo. Treatment with 2-5A-anti-hTR signi®cantly suppressed tumor growth of prostate cancer cells, PC3 and DU145. Cell viability of tumors was reduced to 9 ± 18% after the treatment for 6 days, whereas ®broblast cells without telomerase activity were not sensitive to the treatment with 2-5A-anti-hTR. In PC3 cells, apoptosis was observed in about 74% of the remaining cells after 3 days of the treatment. Interestingly, the activation of caspases was involved in the cytotoxic eect of 2-5A-anti-hTR. Furthermore, tumor growth of subcutaneous xenografts of prostate cancer cells was signi®cantly inhibited with the treatment through induction of apoptosis.
Inhibition of telomerase function is expected to be a promising therapy for cancers, because telomerase is predominantly detected in tumors (Kim, 1997) . Recently, the treatment with antisense hTR alone was reported to inhibit telomerase activity by using cultured melanoma cells (Glukhov et al., 1998) . It was also reported that inhibition of telomerase activity by peptide nucleic acids was stronger than phosphorothioate oligonucleotides (Norton et al., 1996) . Furthermore, hTR was degraded by hammerhead ribozyme (Kanazawa et al., 1996) . All of these works demonstrated the eect on telomerase inhibition using in vitro system only. Additionally, these showed the eect on telomerase inhibition, but not on cell viability. To investigate whether telomerase inhibition is available for cancer treatment, it is important to assess its eect on tumor growth using in vitro and in vivo systems. As demonstrated in this study, we succeeded in treating tumor models in vitro and in vivo with 2-5A-anti-hTR. Therefore, our approach is expected to be available for the treatment of a wide range of tumors including prostate cancer.
In this study, we detected 74% of apoptotic PC3 cells just 3 days after 2-5A-anti-hTR treatment. This time course is signi®cantly shorter than previous reports using the antisense hTR vector (Kondo et al., 1998b; Feng et al., 1995) . Feng and colleagues (1995) ®rst demonstrated that the cell crisis of HeLa cells at 23 ± 26 population doublings after a transfection with antisense hTR vector. Our previous study has shown that using the same vector, malignant glioma U251-MG cells underwent either dierentiation or apoptosis at 30 doublings after transfection (Kondo et al., 1998b) . It took approximately 1 month to induce apoptotic cell death in tumor cells following telomerase inhibition by transfection of antisense hTR vector. In contrast, it took just 3 days to detect apoptosis in the majority of prostate cancer cells treated with 2-5A-antihTR in the present study. Does it depend on tumor cell types? It is unlikely, because not only prostate cancer cells, but also HeLa and U251-MG cells underwent apoptosis in more than 70% of cells 3 ± 6 days after 2-5A-anti-hTR treatment (unpublished data). What is the dierence in molecular mechanisms between the antisense hTR vector system and 2-5A-anti-hTR treatment? Judging from previous reports with the antisense hTR vector (Kondo et al., 1998b; Feng et al., 1995) and this study with 2-5A-anti-hTR, it is possible to raise the following possibility. Transfection of tumor cells with the antisense vector against hTR inhibited telomerase activity, resulting in the critical shortening of telomeric DNA (Feng et al., 1995) . Until then, tumor cells were able to grow progessively and the expression status of caspase family or CDKIs was not changed. When the telomere length reached the critical length, the apoptotic pathway was triggered. On the other hand, treatment with 2-5A-anti-hTR degraded hTR and inhibited telomerase activity as the antisense vector system did (Kondo et al., 1998a) . The present ®ndings indicated the involvement of caspase family, although we cannot exclude the possibility that caspase inhibitors might in¯uence the eect of 2-5A-anti-hTR oligonucleotides or the activity of Lipofectaminemediated delivery system to some extent. 2-5A-antihTR may mainly trigger the execution of apoptosis through activation of caspase family. Furthermore, the 2-5A-anti-hTR treatment enhanced the expressions of p16 and p27. CDKIs are reported to either inhibit or stimulate apoptosis pathway on a case-by-case basis (Kondo et al., 1996; Wang and Walsh, 1996) . The upregulation of p16 and p27 expressions may contribute to the execution of apoptosis. More recently, by using p27-overexpressing tumor cells that are regulated by the tetracyclin system, we have obtained evidence that p27 plays a role of a positive regulator of apoptosis in 2-5A-anti-hTR treatment (unpublished data). We are presently investigating the role of p16 in cytotoxic eect of 2-5A-anti-hTR. Taken together, these ®ndings raised the possibility that the antitumor eect of 2-5A-anti-hTR might be independent of telomere shortening.
Recent advances in the understanding of the molecular biology of prostate cancer have led to the development of new treatment strategies for tumors (Naitoh et al., 1998) . Gene therapy for prostate cancer is one of promising approaches (Sikora and Pandha, 1997) . However, its utility is limited because of low eciency of therapeutic gene transfection, lack of target speci®city, potential for random insertion of the gene into the genome, instability of gene expression, and immunogenecity, which interferes with delivery of the gene therapy vector to the target cells. Treatment with 2-5A-anti-hTR is speci®c for telomerase RNA, and it is signi®cantly more active than conventional antisense oligonucleotides (Clemens and Williams, 1978; Zhou et al., 1993; Torrence et al., 1993; Maran et al., 1994; Cirino et al., 1997) , suggesting a high potentiality of novel gene therapy.
In summary, 2-5A-anti-hTR treatment eectively inhibited tumor growth in prostate cancer cells in vitro and in vivo, indicating that 2-5A-anti-hTR is a promising therapeutic agent for the treatment of prostate cancer with telomerase activity. Its eect is mainly due to induction of apoptosis by activated caspases. This is the ®rst report indicating the feasibility of antisense telomerase therapy for prostate cancer.
Materials and methods

Cells
Human prostate cancer cell lines PC3 and DU145 as target cells, and normal ®broblast cells MRC5 and WI38 as control cells were purchased from ATCC (American Tissue Culture Collection, Rockville, MD, USA). Cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM, GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal calf serum (GIBCO BRL), 4 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Telomerase activity (TRAP) assay
The TRAP assay was performed using the TRAPEZE TM Telomerase Detection Kit (Oncor Inc., Gaithernburg, MD, USA) following the manufacturer's instructions with some minor modi®cations as previously described (Kondo et al., 1998a) . Cells were washed once in PBS and homogenized in 50 ml of ice-cold lysis buer. After 30 min of incubation on ice, the lysates were centrifused at 10 000 g for 15 min at 48C, and the supernatant was rapidly frozen and stored at 7808C. The concentration of protein was measured using the BioRad Protein Assay (Richmond, CA, USA). Equal amounts of protein extracts were used for each telomerase assay. Two ml (100 ng) of each extract was assayed in 50 ml of reaction mixture containing 5 ml of 106TRAP reaction buer, 50 mM deoxynucleotide triphosphates, 0.2 to 0.4 ml of [a-32 P]dCTP (10 mCi/ml, 3000 Ci/mM), 0.1 mg of TS primers, 1 ml of Primer Mix, 1 mg of T4 gene 32 protein (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA) and 2 units of Taq DNA polymerase (Boehringer Mannheim Biochemicals Indianapolis, IN, USA). An internal telomerase activity standard (ITAS, 36 bp) was included in the Primer Mix. After a 30-min incubation at room temperature for telomerase extension, the reaction mixture was then subjected to PCR ampli®cation in a thermal cycler with 30 cycles at 948C for 30 s, 508C for 30 s, and 728C for 1.5 min. The PCR product was electrophoresed in 0.56tris-borate EDTA on a 6% polyacrylamide gel. The gel was then dried, and autoradiography was performed. Radioactivity levels were quantitated with a Molecular Dynamics PhosphorImager (Sunnyvale, CA, USA).
Synthesis of 2-5A-anti-hTR
The selection of the antisense against hTR was described previously (Kondo et al., 1998a) . Brie¯y, we designed the 2-5A antisense oligonucleotide to the region between residues 76 and 94, because this part was predicted to be the most open using the MFOLD program. The sequence of the antisense oligonucleotide is 5'-GCG CGG GGA GCA AAA GCA C-3'. To investigate the eect of 2-5A-anti-hTR, we synthesized a test oligonucleotide (spA 4 -anti-hTR) with complete homology to the targeted sequence and two controls. One is spA 2 -anti-hTR which is non-functional 2-5A linked to the antisense hTR. The other control oligonucleotide is spA 4 -anti-(M6)hTR, which contains functional 2-5A, but there are six mismatched nucleotides in the antisense which would prevent homologous binding with the telomerase RNA. These chimeric oligonucleotides were synthesized on solid supports and puri®ed as described previously (Torrence et al., 1993; Cirino et al., 1997; Xiao et al., 1994) or were synthesized at and purchased from Hybridon (Milford, MA, USA).
Cell viability assay
The cytotoxic eect of 2-5A-anti-hTR on tumor cells was determined by using trypan blue dye exclusion assays as described previously (Kondo et al., 1998a) . The cells were seeded at 5610 3 cells/well (0.1 ml) in 96-well¯at-bottomed microtiter plates and incubated overnight at 378C. Then, oligonucleotides mixed with Lipofectamine (GIBCO BRL) were added to the cells every 24 h. The ®rst day of the treatment was designated as Day 0. The cell viability of treated cells was expressed as a percentage of control cells.
TUNEL assay
To determine whether treatment with 2-5A-anti-hTR induced apoptosis, tumor cells and tissues were stained by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) technique, using the ApopTag kit (Oncor Inc.) as described previously (Kondo et al., 1996) .
Ribonuclease protection assay
To investigate the molecular mechanisms responsible for the anticancer eect of 2-5A-anti-hTR, the expression levels of mRNA in apoptosis-related genes and cell cycle-related genes were examined by a ribonuclease (RNase) protection assay kit (hAPO-1c, hAPO-2 and hCC-1, RiboQuant, Pharmingen, San Diego, CA, USA) according to the manufacturer's instructions. Two housekeeping genes (L32 and GAPDH) were used as controls. Total RNA from tumor cells treated with control or test oligonucleotides in the presence of Lipofectamine was isolated. Then, a multiprobe antisense RNA was synthesized by using an appropriate template and [a-32 P]-dUTP. The probe set was hybridized in excess to target RNA and then digested with RNase. The RNaseprotected probes were puri®ed, resolved on a denaturing polyacrylamide gel, and shown by autoradiography. Each level of radioactivity was quantitated and normalized by level of GAPDH with a Molecular Dynamics PhosphorImager.
Caspase inhibition assay
Functional involvement of caspases was examined with inhibition of the enzymes. Cells were seeded at 5610 3 cells/ well (0.1 ml) in 96-well¯at-bottomed microtiter plates and incubated overnight at 378C. Every 24 h the cells were preincubated for 1 h with either ICE inhibitor or CPP32 inhibitor (Biomol Research Laboratories, Inc., Plymouth Meeting, PA, USA) solubilized in DMSO at the concentration of 100 mM of each inhibitor. Then, the cells were treated with 0.5 mM spA 4 -anti-hTR mixed with Lipofectamine in the presence of one of the inhibitors (100 mM). The cell viability was determined as described above.
In vivo treatment PC3 prostate cancer cells (1.0610 6 cells in 0.05 ml serum free DMEM and 0.05 ml Matrigel) were inoculated subcutaneously into the right¯ank of 8 ± 12 week-old female Balb/c nude mice (®ve mice for each treatment group), respectively. Tumor growth was monitored using calipers every 2 or 3 days. Tumor volume (V) was calculated as (L6W 2 )/2, where L=length (mm) and W=width (mm). Oligonucleotide treatment was initiated when the tumors reached a mean tumor volume of 50 mm 3 . spA 4 -anti-hTR or spA 4 -anti-(M6)hTR (1 nmol/20 ml of distilled water) mixed with Lipofectamine (0.3 ml) was administrated by injection directly into the tumor every 24 h for 7 days. Mice were sacri®ced by cervical dislocation 1 day after the ®nal injection. The tumors were then removed, frozen rapidly, and 12 ml sections were made and used for histological studies. During all of these experiments the animals were housed and handled in accordance with the National Institutes of Health guidelines.
Statistical analysis
The data were expressed as means+standard deviation (s.d.). Statistical analysis was performed by Student's t-test (twotailed). The criterion for statistical signi®cance was taken as P50.05.
